Clinical Trials Logo

Atypical Teratoid/Rhabdoid Tumor clinical trials

View clinical trials related to Atypical Teratoid/Rhabdoid Tumor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02962167 Completed - Clinical trials for Atypical Teratoid/Rhabdoid Tumor

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Start date: February 22, 2017
Phase: Phase 1
Study type: Interventional

This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).

NCT ID: NCT01331135 Completed - Clinical trials for Renal Cell Carcinoma

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

Aflac ST0901
Start date: April 2011
Phase: Phase 1
Study type: Interventional

The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy. These treatments can prolong their life but may not offer a long-term cure. This study proposes using a drug called Sirolimus in combination with common chemotherapy drugs to treat patients with recurrent and refractory solid tumors. Sirolimus has been found to inhibit cell growth and to have anti-tumor activity in pediatric solid tumors in previous studies and, therefore, has the potential to increase the effectiveness of the chemotherapy drugs when given together. This study wil investigate the highest dose of Sirolimus that can be given orally with other oral chemotherapy drugs. Cohorts of 2 subjects will be started at the minimum dose. The dose will be increased in the next 2 subjects as long as there were no major reactions in the previous groups. This study will also seek to learn more about the side effects of sirolimus when used in this combination and what effects the drug has on the white cells and the immune system. Successful use of this drug will impact the cancer population greatly by providing an increased chance of survival to those with resistant or recurrent cancers.